Dr Reddys Laboratories (RDY) Total Current Liabilities (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Total Current Liabilities of $1.8 billion for Q1 2026, up 17.03% year-over-year from $1.5 billion in Q1 2025, and up 17.03% quarter-over-quarter from $1.5 billion in Q1 2025.
Dr Reddys Laboratories (RDY) Total Current Liabilities (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 17.03% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 17.03% YoY), while the FY2026 annual figure was $1.8 billion, up 17.03% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $1.8 billion, up from $1.5 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $1.8 billion in Q1 2026, with the low at $1.0 billion in Q1 2023.
- The 5-year median for Total Current Liabilities is $1.2 billion (2022), against an average of $1.3 billion.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities retreated 15.74% in 2023, then surged 32.55% in 2025.
- Dr Reddys Laboratories' Total Current Liabilities stood at $1.2 billion in 2022, then retreated by 15.74% to $1.0 billion in 2023, then increased by 10.34% to $1.2 billion in 2024, then soared by 32.55% to $1.5 billion in 2025, then climbed by 17.03% to $1.8 billion in 2026.
- Business Quant data shows RDY's Total Current Liabilities at $1.8 billion in Q1 2026, $1.5 billion in Q1 2025, and $1.2 billion in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.00 Bn | 43.04 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.78 Bn | 30.10 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.92 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.21 Bn | 19.54 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.15 Bn | 7.50 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.79 Bn |
| Mar 31, 2025 | 1.53 Bn |
| Mar 31, 2024 | 1.15 Bn |
| Mar 31, 2023 | 1.04 Bn |
| Mar 31, 2022 | 1.24 Bn |
| Mar 31, 2021 | 1.14 Bn |
| Mar 31, 2020 | 966.00 Mn |
| Mar 31, 2019 | 863.00 Mn |
| Mar 31, 2018 | 1.07 Bn |
| Dec 31, 2009 | 472.00 Mn |
| Sep 30, 2009 | 500.00 Mn |
| Jun 30, 2009 | 531.00 Mn |